ArticleAntibiotics (Basel, Switzerland)2020
Antibiotic Resistance and Therapy Outcome in
Article in Antibiotics (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Empirical therapy versus tailored therapy for Helicobacter pylori infection? A systematic review.BMC infectious diseases · 2025Pooled it
- Efficacy of 10 days high-dose and double-dose rabeprazole-based concomitant therapy for Helicobacter pylori eradication among Lebanese population: a pilot randomized controlled trial.BMC gastroenterology · 2025Trial
- Application of a semi-automatic, intensive follow-up for improving efficacy and adherence of Helicobacter pylori eradication therapy: A randomized controlled trial.MicrobiologyOpen · 2021Trial
- The interval of rescue treatment does not affect the efficacy and safety of Helicobacter pylori eradication: A prospective multicenter observational study.Chinese medical journal · 2025Observational
- The use of real-world evidence to generate cost analysis of antibiotic susceptibility testing (AST) in patients withHeliyon · 2024Article
- Genetic Determinants of Clarithromycin and Fluoroquinolones Resistance inAntibiotics (Basel, Switzerland) · 2024Article
- Antimicrobial resistance among migrants in Europe: a systematic review and meta-analysis - update from 2017 to 2023.EClinicalMedicine · 2024Article
- Antimicrobial susceptibility of clinicalMicrobiology spectrum · 2024Article
- Review
- Antibiotic Resistance and Therapeutic Efficacy ofAntibiotics (Basel, Switzerland) · 2023Article
- Rifabutin as salvage therapy forWorld journal of gastroenterology · 2022Review
- Clinical Implications ofAntibiotics (Basel, Switzerland) · 2022Review
- Empirical vs. Susceptibility-Guided Treatment ofFrontiers in microbiology · 2022Article
- Rescue Therapies forAntibiotics (Basel, Switzerland) · 2021Article
- Antimicrobial Efficacy of Five Probiotic Strains Against Helicobacter pylori.Antibiotics (Basel, Switzerland) · 2020Article
- Empirical or susceptibility-guided treatment forTherapeutic advances in gastroenterology · 2020Review
- Culture-based antibiotic susceptibility testing forAnnals of gastroenterologyArticle
- Success of 14-day triple and quadruple therapy for the control ofDrug target insightsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimto evaluate the development of antibiotic resistance, MIC values trends and therapeutic outcomes in patients who failed at least one H. pylori eradication therapy.
methodsconsecutive patients, referred to perform upper gastrointestinal endoscopy (UGIE) to our Unit from January 2009 to January 2019 following at least one therapeutic attempt were considered. Bacterial resistance towards clarithromycin, metronidazole and levofloxacin was tested. Patients received either a susceptibility-guided therapy or Pylera®.
resultsa total of 1223 patients were H. pylori positive, and antibiotic susceptibility was available for 1037. The rate of antibiotic resistance and MIC values significantly increased paralleling the number of previous therapeutic attempts. Eradication rates of antibiogram-tailored therapies remained stable, except for the sequential therapy if used as a third line. As a rescue treatment, the Pylera® therapy achieved cure rates comparable to those of the other culture-guided therapies.
conclusionsA significant increase in the secondary resistance towards the three tested antibiotics was observed, both as rate and MIC values, in correlation with the number of therapy failures. These findings should be considered when administering an empirical second-line therapy. Pylera® therapy eradication rates are comparable to culture-tailored therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.